Pharmaceutical firm PT Kalbe Genexine Biologics (KGBio), a Kalbe Farma (KLBF) unit, signed a license agreement with South Korea’s Genexine to develop and commercialize Efineptakin Alpha, which is a long-acting interleukin-7 that uses the HyFc Genexine technology platform.

To subscribe please click here